12/2
01:05 pm
gpcr
Structure Therapeutics (NASDAQ:GPCR) was given a new $50.00 price target on by analysts at Stifel Nicolaus.
Medium
Report
Structure Therapeutics (NASDAQ:GPCR) was given a new $50.00 price target on by analysts at Stifel Nicolaus.
11/28
07:02 am
gpcr
Structure Therapeutics (NASDAQ:GPCR) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Structure Therapeutics (NASDAQ:GPCR) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/24
07:02 am
gpcr
Structure Therapeutics (NASDAQ:GPCR) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Structure Therapeutics (NASDAQ:GPCR) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
11/16
10:26 pm
gpcr
BMO Capital Remains Bullish on Structure Therapeutics (GPCR), Cites Upcoming Trial Readouts [Yahoo! Finance]
Low
Report
BMO Capital Remains Bullish on Structure Therapeutics (GPCR), Cites Upcoming Trial Readouts [Yahoo! Finance]
11/6
04:01 pm
gpcr
Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
Low
Report
Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
10/28
10:59 am
gpcr
Structure Therapeutics (NASDAQ:GPCR) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Low
Report
Structure Therapeutics (NASDAQ:GPCR) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
10/21
07:28 am
gpcr
Structure Therapeutics (NASDAQ:GPCR) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Medium
Report
Structure Therapeutics (NASDAQ:GPCR) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
10/3
03:45 pm
gpcr
Structure Therapeutics (NASDAQ:GPCR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Structure Therapeutics (NASDAQ:GPCR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/3
01:48 pm
gpcr
Structure Therapeutics: The Dark Horse In The Oral Obesity GLP-1 Arena [Seeking Alpha]
Low
Report
Structure Therapeutics: The Dark Horse In The Oral Obesity GLP-1 Arena [Seeking Alpha]
9/21
09:35 am
gpcr
Structure Therapeutics Inc. (GPCR) Eyes Major 2025 Catalyst With Phase 2b Obesity Data [Yahoo! Finance]
Medium
Report
Structure Therapeutics Inc. (GPCR) Eyes Major 2025 Catalyst With Phase 2b Obesity Data [Yahoo! Finance]
9/10
07:54 am
gpcr
Structure Therapeutics (NASDAQ:GPCR) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.
Low
Report
Structure Therapeutics (NASDAQ:GPCR) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.